ImmunityBio, Inc.
IBRX
Rank in Stocks
#2232
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Share Price
$8.55
Last synced: 2026-10-19
Market Cap
$9.06B
Change (1 day)
-6.84%
Change (1 year)
249.08%
Country
US
Trade ImmunityBio, Inc. (IBRX)
Category
Healthcare
P/E ratio for ImmunityBio, Inc. (IBRX)
P/E ratio as of October 2026 TTM: -10.18
According to ImmunityBio, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.18. At the end of 2023 the company had a P/E ratio of -4.38.
P/E ratio history for ImmunityBio, Inc. from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -10.18 | 135.62% |
| 2024 | -4.32 | -1.41% |
| 2023 | -4.38 | -9.88% |
| 2022 | -4.86 | -28.18% |
| 2021 | -6.76 | -70.31% |
| 2020 | -22.78 | 151.26% |
| 2019 | -9.07 | 131.41% |
| 2018 | -3.92 | -73.38% |
| 2017 | -14.72 | -5.37% |
| 2016 | -15.56 | -34.84% |
| 2015 | -23.87 | -98.64% |
| 2014 | -1.76K | -86.95% |
| 2013 | -13.49K | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -382.76% |
US
|
|
| -28.36 | 178.61% |
US
|
|
| -24.57 | 141.36% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -397.98% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.